Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2529-2536

  Frasci, Giuseppe ^a   Lorusso, Vito ^a   Panza, Nicola ^a   Comella, Pasquale ^a   Nicolella, Gianpaolo ^a   Bianco, Andrea ^a   De Cataldis, Giuseppe ^a   Iannelli, Annunziato ^a   Bilancia, Domenico ^a   Belli, Mario ^a   Massidda, Bruno ^a   Piantedosi, Francovito ^a   Comella, Giuseppe ^a   De Lena, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; NAVELBINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033932224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2529     Document Type: Article

References (30)

1. Fry WA, Menck HR, Winchester DP, et al: The National Cancer Data Base report on lung cancer. Cancer 77:1947-1955, 1996
2. Non-Small Cell Lung Cancer Cooperative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patient data from 52 randomised clinical trials. BMJ 311: 899-909, 1995
3. Oshita F, Kurata T, Kasai T, et al: Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86:1198-1202, 1995
4. Souquet PJ, Bombaron P, Brunel-Crova J, et al: Treatment of advanced and disseminated non-small cell lung cancer in elderly patients: Results of the MIC regimen. Lung Cancer 18:24, 1997 (suppl 1, abstr 82)
5. Janssen-Heijrten ML: Prevalence of comorbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 21:105-113, 1998
6. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older patients. J Clin Oncol 16:582-587, 1998
7. Colleoni M, Geion F, Nelli P, et al: Weekly vinorelbine in elderly patients with non-small cell lung cancer. Tumori 80:448-452, 1994
8. Gridelli C, Perrone F, Gallo C, et al: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer: A two-stage phase II study. Eur J Cancer 33:392-397, 1997
9. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
10. Gatzmeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer. Eur J Cancer 32:243-248, 1996
11. Shepherd FA, Abratt RP. Anderson H, et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24:50-55, 1997 (suppl 7)
12. Lorusso V, Carpagnano F, Frasci G, et al: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18:405-411, 2000
13. Charlson ME, Pompei P, Ales K, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
14. Hollen PJ, Gralla RJ, Kris MG, et al: Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale. Eur J Cancer 29A:S51-S58, 1993 (suppl 1)
15. Frasci G, Comella P, Panza N, et al: Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients: Gruppo Oncologico Cooperative Sud-Italia. Eur J Cancer 34:1710-1714, 1998
16. Comella P, Frasci G, Panza N, et al: Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 17:1526-1534, 1999
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
19. Schaid DJ, Wieand S. Therneau TM: Optimal two-stage screening designs for survival comparisons. Biometrika 77:507-513, 1990
20. Cox DR: Regression models and life tables. J R Stat Assoc 34:187-220, 1972
21. Cormier Y, Bergeron D, LaForge J, et al: Benefits of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 50:845-849, 1982
22. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
23. Kaasa S, Lund E, Thorud E, et al: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67:2443-2447, 1991
24. Martoni A, Di Fabio F, Guaraldi M, et al: Gemcitabine as single-agent in the treatment of elderly patients with stage IIIB-IV non-small cell lung cancer: Preliminary results of an Italian multicenter phase II study. Proc Am Soc Clin Oncol 18:517a, 1999 (abstr 1991)
25. Nguyen B, Sandler A, Denham C: The safety and efficacy of gemcitabine plus cisplatin in the elderly chemonaive patients (age > 70 years) as compared to those with age < 70 years. Proc Am Soc Clin Oncol 18:471a, 1999 (abstr 1818)
26. Lippe P, Silva RR, Monterubbianesi MC, et al: Advanced non-small cell lung cancer (ANSCLC) in the elderly: Symptoms-relief after weekly gemcitabine (G) and cisplatin (P). Proc Am Soc Clin Oncol 18:514a, 1999 (abstr 1984)
27. Esteban E, Llano J, Vieitez JM, et al: Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Proc Am Soc Clin Oncol 17:482a, 1998 (abstr 1855)
28. Isokangas OP, Mattson K, Joensuu H, et al: A phase II study of vinorelbine (VNR) and gemcitabine (GEM) in inoperable stage IIIB-IV NSCLC. Proc Am Soc Clin Oncol 17:489a, 1998 (abstr 1882)
29. Herbst RS, Khuri M, Jung N, et al: Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 18:462a, 1999 (abstr 1782)
30. Gridelli C, Frontini L, Giulisano M, et al: Optimal doses of gemcitabine + vinorelbine (Gemvin) in the treatment of advanced non-small-cell lung cancer (NSCLC): A "Keep-the-Winner" phase 2 study. Proc Am Soc Clin Oncol 18:477a, 1999 (abstr 1841)